129 related articles for article (PubMed ID: 16984144)
1. Chemical conjugate TMV-peptide bivalent fusion vaccines improve cellular immunity and tumor protection.
McCormick AA; Corbo TA; Wykoff-Clary S; Palmer KE; Pogue GP
Bioconjug Chem; 2006; 17(5):1330-8. PubMed ID: 16984144
[TBL] [Abstract][Full Text] [Related]
2. TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models.
McCormick AA; Corbo TA; Wykoff-Clary S; Nguyen LV; Smith ML; Palmer KE; Pogue GP
Vaccine; 2006 Sep; 24(40-41):6414-23. PubMed ID: 16860441
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant.
Jérôme V; Graser A; Müller R; Kontermann RE; Konur A
J Immunother; 2006; 29(3):294-305. PubMed ID: 16699372
[TBL] [Abstract][Full Text] [Related]
4. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
5. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
6. Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy.
Masuko K; Wakita D; Togashi Y; Kita T; Kitamura H; Nishimura T
Immunol Lett; 2015 Jan; 163(1):102-12. PubMed ID: 25479286
[TBL] [Abstract][Full Text] [Related]
7. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK
Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151
[TBL] [Abstract][Full Text] [Related]
8. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
10. Assembly of trans-encapsidated recombinant viral vectors engineered from Tobacco mosaic virus and Semliki Forest virus and their evaluation as immunogens.
Smith ML; Corbo T; Bernales J; Lindbo JA; Pogue GP; Palmer KE; McCormick AA
Virology; 2007 Feb; 358(2):321-33. PubMed ID: 17014881
[TBL] [Abstract][Full Text] [Related]
11. Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications.
Smith ML; Lindbo JA; Dillard-Telm S; Brosio PM; Lasnik AB; McCormick AA; Nguyen LV; Palmer KE
Virology; 2006 May; 348(2):475-88. PubMed ID: 16466765
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein-antigen fusions lose their enhanced immunostimulatory capacity after endotoxin depletion.
Marincek BC; Kühnle MC; Srokowski C; Schild H; Hämmerling G; Momburg F
Mol Immunol; 2008 Nov; 46(1):181-91. PubMed ID: 18804283
[TBL] [Abstract][Full Text] [Related]
13. A novel mimovirus vaccine containing survivin epitope with adjuvant IL-15 induces long-lasting cellular immunity and high antitumor efficiency.
Yang Z; Wang L; Wang H; Shang X; Niu W; Li J; Wu Y
Mol Immunol; 2008 Mar; 45(6):1674-81. PubMed ID: 18035418
[TBL] [Abstract][Full Text] [Related]
14. Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes.
Schutze-Redelmeier MP; Kong S; Bally MB; Dutz JP
Vaccine; 2004 May; 22(15-16):1985-91. PubMed ID: 15121311
[TBL] [Abstract][Full Text] [Related]
15. Generation of autoreactive CTL by tumour vaccines containing foreign T helper epitopes.
Steinaa L; Rasmussen PB; Rygaard J; Mouritsen S; Gautam A
Scand J Immunol; 2007 Mar; 65(3):240-8. PubMed ID: 17309778
[TBL] [Abstract][Full Text] [Related]
16. Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFlk-1.
Wang YS; Wang GQ; Wen YJ; Wang L; Chen XC; Chen P; Kan B; Li J; Huang C; Lu Y; Zhou Q; Xu N; Li D; Fan LY; Yi T; Wu HB; Wei YQ
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6779-87. PubMed ID: 18006780
[TBL] [Abstract][Full Text] [Related]
17. Enhanced generation of cytotoxic T lymphocytes by increased cytosolic delivery of MHC class I epitope fused to mouse heat shock protein 70 via polyhistidine conjugation.
Takemoto S; Nishikawa M; Otsuki T; Yamaoka A; Maeda K; Ota A; Takakura Y
J Control Release; 2009 Apr; 135(1):11-8. PubMed ID: 19100299
[TBL] [Abstract][Full Text] [Related]
18. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
19. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope.
Lu Y; Ouyang K; Fang J; Zhang H; Wu G; Ma Y; Zhang Y; Hu X; Jin L; Cao R; Fan H; Li T; Liu J
Vaccine; 2009 Aug; 27(39):5411-8. PubMed ID: 19616501
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S; Wang F; He X; He Y; Li D; Sun S
Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]